	2	
	3	What is claimed is:
	4	
	5	Claim 1. A method for diagnosing or monitoring
	6	multiple sclerosis (MS) in a mammal comprising:
	7	obtaining a sample of body fluid from said mammal, wherein
	8	said body fluid includes blood, blood products and saliva;
	9	contacting said sample with at least one protein
	10	associated with multiple sclerosis, wherein said contacting is
	11	by an enzyme-linked immunosorbent assay (ELISA);
THE	12	determining a level of at least one autoantibody specific
	13	for said at least one protein in said sample; and,
4 4	14	comparing said level of said at least one autoantibody
i in	15	with statistically significant levels thereof, wherein
-	16	diagnosis or monitoring of MS in said mammal is achieved.
	17	
	18	Claim 2. The method of claim 1, wherein said mammal is a
	19	human.
	20	
	21	Claim 3. The method of claim 1, wherein said protein is myelin
	22	basic protein (MBP).
	23	
	24	Claim 4. The method of claim 1, wherein said ELISA comprises
	25	the steps of:

CLAIMS

-51-

1

<u>u</u>
4D
Q
Ŋ
<u>L</u> L
, 12 m
din m
5
ļ.
ļui.
<u>l</u> ab
ufus Eta
i i

1	mixing said sample with at least one compound effective to
2	optimize the signal to noise ratio;
3	contacting said sample with an immunosorbent comprising
4	said at least one protein having a high specific affinity for
5 .	said at least one autoantibody; and,
6	determining an amount of said at least one autoantibody
7	bound by said at least one protein on said immunosorbent using
8	an antibody composition having an affinity for said at least
9	one autoantibody and operably linked to a signal generating
10	system.
11	
12	Claim 5. The method as in claim 4, wherein said signal
13	generating system is a tetramethylbenzidine substrate.
14	
15	Claim 6. The method as in claim 4, wherein said at least one
16	autoantibody is anti-MBF IgG.
17	
18	Claim 7. The method as in claim 6, wherein said antibody
19	composition comprises purified anti-human IgG conjugated to
20	horseradish peroxidase.
21	
22	Claim 8. The method as in claim 4, wherein said at least one
23	autoantibody is anti-MBP IgM.
24	
25	Claim 9. The method as in claim 8, wherein said antibody

Ę
Ü
ű
N
ظظ
, F. J.
4
€
**
Li
••
ļ. Ļi

composition comprises purified anti-human IgM conjugated to
horseradish peroxidase.
Claim 10. The method as in claim 4, wherein said at least one
autoantibody includes anti-MBP IgG and anti-MBP /gM.
Claim 11. A kit for diagnosing multiple sclerosis (MS) or
monitoring disease state in MS patients, comprising:
at least one biomolecule or an immunologically detectable
fragment thereof which is upregulated in MS patients, said
biomolecule having an affinity for at least one additional
biomolecule whose presence is diagnostic of MS, said at least
one biomolecule being immobilizable on a solid support; and,
at least one labeled biomolecule having a binding affinity
for said at least one additional biomolecule;
whereby performance of at least one analysis determinative
of the presence of statistically significant levels of said at
least one biomolecule or an immunologically detectable fragment
thereof, is carried out on a sample of body fluid and provides
a means for diagrosing or monitoring disease state.
Claim 12. The kit as defined in claim 11, wherein said sample
of body fluid is blood, blood products, or saliva.
Claim 13. The kit as defined in claim 11, wherein said at

1 least one biomolecule is myelin basic protein (MBP)/ 2 3 Claim 14. The kit of claim 11, wherein said/at least one 4 additional biomolecule includes anti-MBP IgM and anti-MBP IgG. 5 6 Claim 15. The kit as defined in claim 11, wherein said at 7 least one additional biomolecule is anti-MBP IgM. 8 9 Claim 16. The kit as defined in claim 15, wherein said labeled 10 biomolecule is anti-human IqM $\not c$ onjugated to horseradish peroxidase. The kit as defined in claim 11, wherein said at least one additional biomoxecule is anti-MBP IgG. Claim 18. The kit as defined in claim 17, wherein said labeled anti/-haman biomolecule is IqG conjugated to horseradish peroxidase. 19 The/kit of claim 11, wherein said monitoring is 20 Claim 19. 21 carried out on a single sample 22

22

Claim 20. The kit of claim 11, wherein said monitoring is carried out on multiple samples such that at least one analysis is carried out on a first sample and at least another analysis

	2	
	2	
	4 5 6 7 8	
	5	
	6	
	7	
	9	
	10	
	11	
w Z	12	
	13	
, , , , , , , , , , , , , , , , , , ,	14	
	15	
jek Lii	16	
	17	
I) Li	18	
	19	
	20	
	21	
	22	
	23	
	24	
	25	

1

is carried out on a second/sample. The kit of Aaim 20, wherein said first and second Claim 21. samples are obtained at different time periods.